Actualités Corvus Pharmaceuticals Inc - CRVS | Actions NASDAQ

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Current Report Filing (8-k)

0001626971 false 0001626971 2023-06-15 2023-06-15 iso4217:USD xbrli:shares...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Data supported CPI-818’s novel immunotherapy mechanism of action and its potential to provide a platform...

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

BURLINGAME, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a...

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

BURLINGAME, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Notice of Effectiveness (effect)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 NOTICE OF EFFECTIVENESSEffective Date:May 08, 2023 4:30...

Quarterly Report (10-q)

0.170.18465561784655351146556178465535110.170.18004656851146553511465535110001626971--12-312023Q1false24000000001626971us-gaap:CommonStockMember202...

Current Report Filing (8-k)

0001626971 False 0001626971 2023-05-08 2023-05-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATESSECURITIES AND EXCHANGE...

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Updated interim results from CPI-818 Phase 1/1b clinical trial continues to support potential of ITK inhibition...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14AProxy Statement Pursuant to...

Proxy Statement (definitive) (def 14a)

Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 14AProxy...

Current Report Filing (8-k)

0001626971 false 0001626971 2023-04-21 2023-04-21 iso4217:USD xbrli:shares...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

CRVS Actualités

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

Statement of Changes in Beneficial Ownership (4)

Notice of Effectiveness (effect)

Quarterly Report (10-q)

Current Report Filing (8-k)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS) Actualités

Corvus Pharmaceuticals Inc (CRVS)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

CRVS Actualités

Current Report Filing (8-k)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

Statement of Changes in Beneficial Ownership (4)

Notice of Effectiveness (effect)

Quarterly Report (10-q)

Current Report Filing (8-k)

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

Additional Proxy Soliciting Materials (definitive) (defa14a)

Proxy Statement (definitive) (def 14a)

Current Report Filing (8-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application